Citations

Clear

4564 citation(s) found for "Yu, Virginia".

Impact of Anemia on Clinical Outcomes in Atrial Fibrillation Patients on Oral Anticoagulants: A Prognostic Meta‐Analysis
Amin, Ahmed Mazen , Elbenawi, Hossam , Odat, Ramez M. , Elgebaly, Mohamed , Al‐Shammari, Ali Saad , Manasrah, AlMothana , Nakhla, Michael , Ayman, Dina , Ali, Mohamed Ahmed , Helmi, Ahmed , Ternes, Caique M. P. , Zeb, Irfan , Deshmukh, Abhishek , Abuelazm, Mohamed , Ternes, Caique M P , Abdelazeem, Basel , Zeb, Irfan , Deshmukh, Abhishek J , DeSimone, Christopher V , d'Avila, Andre , Odat, Ramez M , Al-Shammari, Ali Saad , Ali, Mohamed Ahmed , Abuelazm, Mohamed , Abdelazeem, Basel , DeSimone, Christopher V.

Mayo Clinic

Journal of Cardiovascular Electrophysiology | December 24, 2024 | Volume: 36 | Issue: 2 | Pages: 430-448

10.1111/jce.16537 | PMID 39716396 Get It

ABSTRACTBackgroundAnemia is frequently observed as a comorbidity in atrial fibrillation (AF), especially in elderly patients and in those on anticoagulation. This has been associated with poor clinical outcomes. We aim to investigate the impact of anemia on clinical outcomes in patients with AF on oral anticoagulation.MethodsWe comprehensively searched PubMed, WOS, SCOPUS, EMBASE, and CENTRAL through March 2024 and conducted a prognostic systematic review and meta‐analysis. All analyses were performed using R V. 4.3.1. This meta‐analysis was registered at PROSPERO (CRD42024556023).ResultsWe included 23 studies comprising 286,781 patients for analysis. Anemia had a significant association with an 84% increase in risk of major bleeding (HR: 1.84 with 95% CI [1.59, 2.13], p < 0.01), a 32% increase in the risk of intracranial hemorrhage (HR: 1.32 with 95% CI [1.10, 1.58], p < 0.01), a 98% increase in the risk of gastrointestinal bleeding (HR: 1.98 with 95% CI [1.67, 2.35], p < 0.01), and a 91% increase in the risk of all‐cause mortality (HR: 1.91 with 95% CI [1.46, 2.51], p < 0.01). However, the impact of anemia did not significantly affect the risk of stroke, transient ischemic stroke (TIA), or systemic embolism (HR: 1.07 with 95% CI [0.93, 1.22], p = 0.36).ConclusionAnemia was significantly associated with an increased risk of major bleeding, intracranial hemorrhage, gastrointestinal bleeding, and all‐cause mortality. However, anemia did not significantly impact stroke, TIA, or systemic embolism.
Implementing the 2024 ACC/AHA Multisocietal PAD guidelines into clinical practice: Key changes from the 2016 guidelines
Cohoon, Kevin P. , Henkin, Stanislav , Tomihama, Roger T. , Thomas, Sneha , Porres‐Aguilar, Mateo , Brunton, Nichole , Hornacek, Deborah , Secemsky, Eric A. , Brunton, Nichole E , Porres-Aguilar, Mateo , Tomihama, Roger , Henkin, Stanislav , Secemsky, Eric A

Mayo Clinic

Vascular Medicine | December 23, 2024 | Volume: 30 | Issue: 1 | Pages: 110-113

10.1177/1358863x241306354 | PMID 39713878 Get It

The Family Anesthesia Experience (FAX): Implementing a Social Support–Focused Wellness Programme Across Multiple Residency Programmes
Martinelli, Susan M. , Tran, Thanh N. , Canter, Courtney , Isaak, Robert S. , Mulaikal, Teresa A., Ladlie, Beth L., Willie, Chelsea, Stahl, David L. , Blanchard, Erin E , Zisblatt, Lara , Hoefnagel, A. L. , Marshall, Julie , Collins, Stephen R., Martin, Timothy W. , Chen, Fei , Ladlie, Beth, Marshall, Julie M , Afroze, Farzana, Jain, Ankit , Keneally, Ryan J.

Mayo Clinic

The Clinical Teacher | December 22, 2024 | Volume: 22 | Issue: 1 | Pages: No page available

10.1111/tct.13853 | PMID 39710581 Get It

ABSTRACT Introduction Lack of social support negatively impacts medical trainees' wellness. Programmes to educate medical trainees and their support persons (SPs) have been developed to improve resident wellness, but implementation of these programmes at other institutions remains unclear. We aimed to demonstrate the feasibility of implementing the Family Anesthesia Experience (FAX) programme across multiple institutions and to assess the programme's utility. Methods FAX includes didactics on wellness, burnout, substance use disorder and institutional resources; a panel of senior residents and their SPs; and small‐group simulations of airway management, common procedures and a high‐fidelity intraoperative code. We assessed the programme qualitatively using semistructured interviews of 20 first year anaesthesiology residents and 20 SPs. Data analysis was performed via a content analysis approach. Results Twelve anaesthesiology programmes of varying size and geographic locations implemented FAX with minor adaptations. Minimal direct costs were incurred for the virtual programme. Participants enjoyed the event overall. Content analysis showed that FAX improved SPs' understanding of residency and communication between SPs and residents, had minimal impact on SPs' stress, reduced residents' interpersonal stress with SPs and modified perceptions on wellness and burnout. We developed a conceptual model in which we propose SPs' understanding and empathy for their residents would improve through FAX, which may improve communication with and support for residents. Conclusion We demonstrated that FAX can be implemented at varying anaesthesiology residency programmes. Family‐oriented educational events like FAX may be an effective approach to improve SPs' understanding of a resident's role, thereby increasing social support for residents.
Stereotactic radiosurgery and fractionated radiation therapy in the management of pituitary tumors
Mantziaris, Georgios , Trifiletti, Daniel M. , Pikis, Stylianos , Sheehan, Jason , Trifiletti, Daniel M , Mantziaris, Georgios

Mayo Clinic

Neuro-Oncology Advances | December 19, 2024 | Volume: 7 | Issue: Supplement_1 | Pages: i58-i68

10.1093/noajnl/vdae010 | PMID 40718388 Get It

Abstract Pituitary tumors require a diverse, multidisciplinary approach in their management. Stereotactic radiosurgery (single or hypofractionated) and fractionated radiotherapy are integral parts of the armamentarium. With the introduction of highly conformal, stereotactic ionizing radiation approaches, the reported tumor control rates and clinical outcomes have improved significantly. This review details the indications, risks, and outcomes of pituitary radiosurgery and radiation therapy, and presents in brief the differences in treatment approaches between stereotactic radiosurgery, fractionated radiation therapy, and proton therapy.
Impact of Evusheld monoclonal antibodies on incidence and severity of COVID-19 in patients with cancer: A retrospective cohort study
Warraich, Fatima, Bhardwaj, Prathna, Jadoon, Yamna, Rastegar, Vida , Loke, Chandravathi, Malleshappa, Sudeep K Siddappa , Bhardwaj, Prathna, Naser, Maryam, Gupta, Kush

Mayo Clinic

No container title available | December 19, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5348984/v1 Get It

Abstract Introduction COVID-19 infection is associated with an increased risk of complications, prolonged hospitalization, and mortality despite vaccination in patients with cancer. Evusheld (tixagevimab-cilgavimab) was granted emergency use approval in December 2021 for pre-exposure prophylaxis based on preliminary results from the PROVENT trial. However, studies evaluating the impact of Evusheld in cancer patients in the real-world are limited. In this study, we assessed the impact of Evusheld on the incidence and severity of COVID-19 infection in cancer patients at our institution. Methods and Materials We conducted a retrospective descriptive study at our institution on patients with current and prior history of cancer diagnosis regardless of treatment history who received Evusheld between December 2021 and March 2022. The primary outcome was incidence of COVID-19 during a 6 month follow up period. Secondary outcomes included rate of hospitalization related to COVID-19 and associated mortality. Results A total of 228 patients were included, 43% of which received 2 doses of Evusheld during the study period. Twenty-nine patients (12.7%, 95% CI 9.4% – 18.7%) developed COVID-19, with an average time to diagnosis of 2.5 months (SD 1.6) from receiving Evusheld. Most had hematologic malignancies (68.4%) and were receiving active chemotherapy (71.5%) at the time of diagnosis. Five (17.2%) patients were hospitalized for COVID-19, of whom 4 had hematological malignancy. One patient with hematological malignancy required mechanical ventilation and died. Conclusion Overall, the incidence of COVID-19 following Evusheld was higher than in the PROVENT trial. Infections appeared to be more common and severe in patients with hematologic malignancies.
A Prospective, Randomized, Noninferiority Study to Evaluate the Safety and Effectiveness of Steerable Ureteroscopic Renal Evacuation Compared with Standard Ureteroscopy: 30-Day Results of the ASPIRE Study
Matlaga, Brian R., Johnson, Brett A. , Page, Jay, Wolf, J. Stuart, Preminger, Glenn M. , Jones, Loren, Sobol, Ilya , Stern, Karen , Cuellar, David, Cobb, Kaitlan, Barsky, Robert I, Medairos, Robert, Marguet, Charles G., Nimmagadda, Naren , Chi, Thomas , Johnson, Brett , Stern, Karen L , Mueller, Thomas J. , Jones, Loren, White, Mark, Levin, Michael

Mayo Clinic

Journal of Endourology | December 19, 2024 | Volume: 39 | Issue: 1 | Pages: 10-18

10.1089/end.2024.0602 | PMID 39699687 Get It

Purpose: We report the first multicenter, prospective, randomized noninferiority controlled trial of steerable ureteroscopic renal evacuation (SURE) for nephrolithiasis treatment. Materials and Methods: Candidates for laser lithotripsy ≥18 years with ≥1 renal stone ≥7 mm and 7–20 mm stone burden were randomized 1:1 SURE vs ureteroscopy (URS). SURE was performed using the CVAC Aspiration System, a novel steerable irrigation–aspiration catheter. The primary efficacy end point was noninferiority in stone-free rate (SFR) based on zero residual fragments (RFs) 30 days postprocedure on noncontrast computed tomography. Secondary end points were superiority tests, stone clearance (percent stone volume reduction), residual stone volume (RSV), SFR (no RF >2 mm), and SFR (no RF >4 mm) 30 days postprocedure. Results: Of the subjects, 123 were randomized and 101 qualified for efficacy analysis (SURE 46 vs URS 55). Despite randomization, baseline URS stone volume was higher (SURE 485.0 ± 432.5 mm 3 vs URS 713.3 ± 558.5 mm 3 ). The primary noninferiority end point was achieved (SURE SFR 48% vs URS SFR 49%, p = 0.027, −1.3% [90% confidence interval; −18%, 15%]). Stone clearance was significantly higher for SURE vs URS subjects (SURE 96.9 ± 5.6% vs URS 92.9 ± 11.6%, p = 0.036); RSV was significantly lower (SURE 14.3 ± 3 0.9 mm 3 vs URS 70.2 ± 144.9 mm 3 , p = 0.012). SURE stone clearance and RSV were independent of baseline stone volume, but for URS degraded with increasing baseline stone volume. Safety was comparable between groups. Conclusions: SFR for SURE subjects was noninferior compared with URS subjects; stone clearance and RSV were significantly better with SURE, independent of baseline stone volume.
Endoscopic pituitary gland transposition techniques to the interpeduncular and prepontine regions: an anatomical study
Nizzola, Mariagrazia , Alam, Yasaman, Leonel, Luciano, Graepel, Stephen , Shinya, Yuki , Link, Michael J. , Celda, María Peris, Torregrossa, Fábio , Graepel, Stephen P, Shinya, Yuki , Pinheiro‐Neto, Carlos

Mayo Clinic

Journal of Neurosurgery | December 13, 2024 | Volume: 142 | Issue: 5 | Pages: 1338-1348

10.3171/2024.7.jns24234 | PMID 39671579 Get It

OBJECTIVE The floor of the third ventricle and the interpeduncular and prepontine regions represent challenging surgical targets. The expanded endoscopic endonasal approach (EEA) with pituitary gland (PG) transposition has been proposed to provide direct access to these anatomical regions. Through the years, different endoscopic PG transposition techniques have been studied and presented. The goal of this study was to compare the techniques, relevant anatomy, and surgical exposure of extradural, intradural, and interdural PG transposition techniques. METHODS Six formalin-fixed, latex-injected cadaveric head specimens were used to perform the EEA with extradural, unilateral interdural, and unilateral intradural PG transpositions. The interpeduncular and prepontine regions and the neurovascular structures located within these cisterns were carefully exposed and analyzed. The maximal cranial, caudal, and lateral accessible points within the surgical field were identified for each approach. Consequently, the relative craniocaudal and horizontal surgical axes were measured to quantify the extent of accessibility of each approach. RESULTS The extradural PG transposition technique provided the largest horizontal extensions and bilateral access to structures within the interpeduncular and prepontine regions; the mean horizontal axis was 17.9 (range 13.9–20.4) mm. The unilateral interdural PG transposition provided wider vertical exposure, with a mean craniocaudal axis of 16.2 (range 13.0–20.9) mm. In this approach, the surgical field was extended cranially above the ipsilateral mammillary body (MB). The unilateral intradural PG transposition provided a similar surgical exposure to the interdural approach, with a mean craniocaudal axis of 14.7 (range 12.9–15.8) mm. The approach required significant manipulation of the PG after opening both periosteal and meningeal dura layers. CONCLUSIONS The extradural PG transposition is indicated for lesions of the upper clivus region that extend bilaterally and do not have a cranial extension beyond the MBs. The inter- and intradural PG transpositions are beneficial for unilateral lesions that extend cranially to the MBs. Both techniques require coagulation of the ipsilateral inferior hypophyseal artery. The intradural technique requires more manipulation of the PG, while the interdural technique requires opening and access to the cavernous sinus. If needed, the intra- and interdural techniques can also be performed bilaterally.
Etrasimod as a Monotherapy or With Concomitant Use of Corticosteroids and/or Aminosalicylates: Results From the ELEVATE UC Clinical Program
Yarur, Andrés , Chiorean, Michael , Allegretti, Jessica R. , Cross, Raymond, Ha, Christina , Goetsch, Martina, McDonnell, Aoibhinn , Dalam, Alexis B, Wu, Joseph , Blanco, David, Abbatemarco, Arcangelo M. , Yarur, Andres J , Ha, Christina , Blanco, David A, Panés, Julián

Mayo Clinic

Inflammatory Bowel Diseases | December 13, 2024 | Volume: 31 | Issue: 8 | Pages: 2144-2153

10.1093/ibd/izae288 | PMID 39671695 Get It

Abstract Background Etrasimod is an oral, once daily (QD), selective sphingosine 1-phosphate1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). We assessed the benefit of etrasimod monotherapy and the impact of concomitant corticosteroids (CS) and/or 5-aminosalicylates (5-ASA) therapy. Methods In ELEVATE UC 52 and ELEVATE UC 12, patients with moderately to severely active UC were randomized 2:1 to etrasimod 2 mg QD or placebo for 52 and 12 weeks, respectively. Oral CS or 5-ASA were allowed at baseline. Patients in the monotherapy subgroup received etrasimod or placebo without concomitant CS and/or 5-ASA at baseline. Predefined primary (clinical remission) and key secondary efficacy endpoints aligned with those from both trials and were assessed at Week 12 and Week 52. Safety was assessed up to Week 52. Results Clinical remission rates at Weeks 12 and 52 were significantly higher for etrasimod compared with placebo in patients receiving monotherapy (Week 12: 26.2% vs 4.8%; Week 52: 35.7% vs 4.0%). Differences vs placebo were statistically significant for all predefined endpoints at both time points in patients receiving monotherapy or etrasimod with concomitant 5-ASA only (all P &lt; .05); numerical differences, due to small sample sizes, vs placebo were observed for all endpoints in the CS only and CS + 5-ASA subgroups. Safety was consistent with the overall population. Conclusions Etrasimod monotherapy showed consistent efficacy and safety vs placebo; no apparent benefit was observed with concomitant CS and/or 5-ASA in patients receiving etrasimod. Clinical trial registration NCT03945188; NCT03996369.
The novel DNA cross-linking agent KL-50 is active against patient-derived models of new and recurrent post-temozolomide mismatch repair-deficient glioblastoma
McCord, Matthew , Sears, Thomas , An, Shejuan, James, C. David , Ruggeri, Bruce , Gueble, Susan , Bindra, Ranjit S. , Horbinski, Craig , Sarkaria, Jann, Bindra, Ranjit , Horbinski, Craig , Sears, Thomas , McCord, Matthew , Wang, Wenxia, Chaliparambil, Rahul Kishore , Sarkaria, Jann N.

Mayo Clinic

Neuro-Oncology | December 11, 2024 | Volume: 27 | Issue: 3 | Pages: 644-651

10.1093/neuonc/noae257 | PMID 39658092 Get It

Abstract Background Acquired resistance to temozolomide (TMZ) chemotherapy due to DNA mismatch repair (MMR) enzyme deficiency is a barrier to improving outcomes for isocitrate dehydrogenase (IDH) wild-type glioblastoma (GBM) patients. KL-50 is a new imidazotetrazine-based therapeutic designed to induce DNA interstrand cross-links, and subsequent double-stranded breaks, in an MMR-independent manner in cells with O-6-methylguanine-DNA methyltransferase (MGMT) deficiency. Previous research showed its efficacy against LN229 glioma cells with MMR and MGMT knockdown. Its activity against patient-derived GBM that model post-TMZ recurrent tumors is unclear. Methods We created MMR-deficient GBM patient-derived xenografts through exposure to TMZ, followed by treatment with additional TMZ or KL-50. We also generated isogenic, MSH6 knockout (KO) patient-derived GBM and tested them for sensitivity to TMZ and KL-50. Results KL-50 extended the median survival of mice intracranially engrafted with either patient-derived TMZ-naïve GBM6 or TMZ-naïve GBM12 by 1.75-fold and 2.15-fold, respectively (P &lt; 0.0001). A low dose (4 Gy) of fractionated RT further extended the survival of KL-50-treated GBM12 mice (median survival = 80 days for RT + KL-50 vs. 71 days KL-50 alone, P = 0.018). KL-50 also extended the median survival of mice engrafted with post-TMZ, MMR-deficient GBM6R-m185 (140 days for KL-50 vs. 37 days for vehicle, P &lt; 0.0001). MSH6 KO increased TMZ IC50 for GBM6 and GBM12 cultures by &gt;5-fold and &gt;12-fold for cell death and live cell count outputs, respectively. In contrast, MSH6-KO actually decreased KL-50 IC50 by 10–80%. Conclusion KL-50-based compounds are a promising new strategy for the treatment of MGMT-deficient, MMR-deficient GBM that recurs after frontline TMZ.